Mirum Pharmaceuticals, Inc. (MIRM) experienced a significant intraday plummet of 11.13% on Thursday, extending losses from pre-market trading.

The sharp decline follows mixed analyst sentiment toward the healthcare company. While several firms including Stifel, Raymond James, and Morgan Stanley raised their price targets on Mirum Pharmaceuticals, RBC Capital Markets lowered its target to $128 from $130 while maintaining an Outperform rating. This downward adjustment from RBC appears to have contributed to investor concerns despite the overall positive outlook from other analysts.

According to FactSet data, Mirum Pharmaceuticals maintains an average buy rating with a mean price target of $122.36. The conflicting signals from analysts, particularly RBC's reduced target, created uncertainty that likely triggered the substantial selling pressure during the trading session.